UNSPSC 51381901: Ebselen

This classification denotes a cyclooxygenase inhibitor and antioxidant with the molecular formula C13H9NOSe, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40X2P7DPGH, chemically known as 1,2-benzisoselenazol-3(2h)-one, 2-phenyl- but generally known as ebselen, which bears US NIH Compound Identifier 3194. European Medicines Agency schedules Ebselen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06439MIG.

UNSPSC 51381901 Ebselen is a Commodity code that does not appear to align with the state and local procurement activity tagged under it. The recent opportunities recorded against this code—naloxone and drug deactivation systems procurement in Florida, a direct-to-manufacturer pharmacy initiative RFI in Texas, and a generic multi-source pharmaceutical and OTC product cooperative purchasing vehicle in Minnesota—involve finished pharmaceutical products, medical supplies, and pharmacy benefit management infrastructure rather than ebselen, a small-molecule organic compound used in specialized research and pharmaceutical development contexts. State and local governments do not appear to be procuring ebselen itself through these channels.

The mismatch between the code's nominal scope and the actual procurement activity suggests either a cataloging error in how opportunities were tagged or that this UNSPSC code sees minimal, if any, relevant state and local demand. No solicitations in the record target ebselen as a line item or primary deliverable. Firms pursuing state and local pharmaceutical, medical supply, or pharmacy benefit contracts should verify code alignment with issuing bodies before responding, as tagging inconsistencies at the commodity level can obscure genuine procurement intent.